More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$6.33B
EPS
-4.08
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.018365
Previous close
$100.73
Today's open
$101.74
Day's range
$94.62 - $104.36
52 week range
$18.15 - $112.79
show more
CEO
Victor Perlroth
Employees
141
Headquarters
Palo Alto, CA
Exchange
NASDAQ Global Market
Shares outstanding
65395553
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Kodiak Sciences Inc. (KOD) Presents at UBS Global Biopharma Conference 2026 Transcript
Kodiak Sciences Inc. ( KOD ) UBS Global Biopharma Conference 2026 November 17, 2026 4:20 AM EST Company Participants Victor Perlroth - Co-Founder, Chairman, CEO & President Conference Call Participants Michael Yee - UBS Investment Bank, Research Division Presentation Michael Yee UBS Investment Bank, Research Division All right. Well, good morning, everyone.
Seeking Alpha • Nov 17, 2026

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.
Zacks Investment Research • Nov 13, 2026

Kodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced In
Kodiak Sciences Inc. is up 1,857% since my November 2024 Hold upgrade; I maintain Hold as its ~$6.8 billion valuation embeds optimistic commercial expectations. Zenkuda's multi-indication BLA submission is set to begin in Q4, with standard FDA review potentially yielding approval in late 2027 or early 2028. KOD's twice-yearly diabetic retinopathy dosing is compelling, but biosimilars and established brands limit penetration; switching well-controlled patients will be difficult.
Seeking Alpha • Nov 13, 2026

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
PALO ALTO, Calif., Nov. 12, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2026.
PRNewsWire • Nov 12, 2026

Kodiak Sciences to Present at Three Upcoming Investor Conferences
PALO ALTO, Calif., Nov. 11, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.
PRNewsWire • Nov 11, 2026

Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review
The top contributors to the Portfolio's relative performance in the quarter were Kodiak Sciences, Flotek Industries, and Hyperliquid Strategies. The most significant detractors from the Portfolio's relative performance in the quarter were Vishay Precision Group, Babcock & Wilcox, and CareDx (not held). The salient changes to positioning this quarter included our increased exposure to Health Care and decreased exposure to Industrials.
Seeking Alpha • Nov 4, 2026

Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?
Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.
Zacks Investment Research • Oct 19, 2026

11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
Schaeffers Research • Oct 12, 2026

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).
PRNewsWire • Oct 7, 2026

Top 3 Health Care Stocks That May Collapse In Q4
As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Benzinga • Oct 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Kodiak Sciences Inc commission-free¹. Build wealth for the long term using automated trading and transfers.